Medicare Enrolled
Dr. Kalust Ucar, M.D.
Hematology & Oncology · Glendale, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ucar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ucar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ucar
Dr. Kalust Ucar is a hematology & oncology specialist in Glendale, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Ucar performed 378,235 Medicare services across 3,580 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ucar received a total of $7,411 from 35 pharmaceutical and/or device companies across 156 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ucar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in CA
$7,411 industry payments
Medicare Practice Summary
Medicare Utilization ↗378,235
Medicare services
Top 1% in CA for hematology & oncology
3,580
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~19,907 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
169,500 | $1 | $4 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
36,420 | $0 | $1 |
| Anti-nausea injection (aprepitant) | 35,360 | $1 | $6 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
26,780 | $0 | $0 |
| Denosumab injection (Prolia/Xgeva) | 23,580 | $18 | $83 |
| Pembrolizumab injection (Keytruda) | 21,600 | $43 | $193 |
| Paclitaxel chemotherapy injection | 18,504 | $0 | $0 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
8,640 | $6 | $26 |
| Anti-nausea injection (ondansetron/Zofran) | 6,980 | $0 | $0 |
| Trastuzumab-anns biosimilar injection, 10 mg An injection of the biosimilar medication trastuzumab-anns (Kanjinti) in a 10 mg dose. |
5,263 | $21 | $93 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
4,224 | $0 | $0 |
| Injection, docetaxel, 1 mg | 4,080 | $1 | $2 |
| Injection, tildrakizumab, 1 mg | 3,500 | $110 | $491 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,709 | $97 | $481 |
| Injection, leucovorin calcium, per 50 mg | 1,395 | $3 | $14 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
1,206 | $14 | $93 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
1,020 | $85 | $381 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
1,007 | $2 | $8 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
833 | $2 | $9 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
811 | $121 | $606 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
761 | $12 | $81 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
495 | $39 | $179 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
436 | $59 | $295 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
364 | $62 | $285 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
356 | $147 | $672 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
335 | $58 | $269 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
295 | $25 | $109 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
256 | $25 | $134 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
244 | $1 | $4 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
233 | $26 | $147 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
181 | $1 | $23 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
161 | $11 | $69 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
136 | $51 | $247 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
125 | $65 | $341 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
117 | $31 | $134 |
| New patient office visit, complex (60-74 min) | 116 | $171 | $821 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
105 | $156 | $448 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
101 | $77 | $394 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 101 | $133 | $603 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
100 | $18 | $88 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
92 | $18 | $84 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
92 | $128 | $623 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
85 | $94 | $431 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
84 | $17 | $81 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
77 | $29 | $220 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
71 | $34 | $200 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
71 | $109 | $467 |
| Prochlorperazine injection, up to 10 mg An injection of prochlorperazine administered in a dose of up to 10 mg. |
71 | $2 | $10 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
65 | $4 | $19 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
51 | $66 | $301 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
46 | $2 | $9 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
45.4% high complexity
53.5% medium
1.1% routine
Industry Payment Transparency
Open Payments through 2023 ↗$7,411
Total received (2018-2023)
Avg $1,482/year across 5 years
Top 36% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
35
Companies
156
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,195 (56.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,215 (43.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023
$125
2021
$1,657
2020
$676
2019
$4,332
2018
$621
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
Incyte Corporation
$125
Top 3 companies account for 100.0% of 2023 payments
All-time payments by company (2018-2023) ›
Exelixis Inc.
$3,415
Astellas Pharma US Inc
$574
Amgen Inc.
$491
Janssen Biotech, Inc.
$310
PFIZER INC.
$299
Pharmacyclics LLC, An AbbVie Company
$210
Bayer HealthCare Pharmaceuticals Inc.
$184
E.R. Squibb & Sons, L.L.C.
$161
Incyte Corporation
$160
Merck Sharp & Dohme Corporation
$146
Daiichi Sankyo Inc.
$127
GlaxoSmithKline, LLC.
$122
Jazz Pharmaceuticals Inc.
$122
Agios Pharmaceuticals, Inc.
$113
AstraZeneca Pharmaceuticals LP
$113
Genentech USA, Inc.
$108
Lilly USA, LLC
$94
Novartis Pharmaceuticals Corporation
$89
GENZYME CORPORATION
$74
Kite Pharma, Inc.
$63
Eisai Inc.
$60
EMD Serono, Inc.
$55
Blueprint Medicines Corporation
$50
Spectrum Pharmaceuticals Inc.
$41
PUMA BIOTECHNOLOGY, INC.
$36
Seagen Inc.
$26
EISAI INC.
$25
Myovant Sciences Inc.
$24
Acceleron Pharma, Inc.
$24
Organon LLC
$21
Gilead Sciences, Inc.
$21
Taiho Oncology, Inc.
$17
Deciphera Pharmaceuticals Inc.
$14
Foundation Medicine, Inc.
$13
Janssen Pharmaceuticals, Inc
$9
Top 3 companies account for 60.5% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · BAVENCIO · BESPONSA · BLENREP · BOSULIF · Bavencio · CABLIVI · Cabometyx · DARZALEX · ELITEK · ERBITUX · EVENITY · Erleada · FOUNDATIONONE · Folotyn · GAVRETO · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · NERLYNX · Nplate · Nubeqa · ONTRUZANT · OPDIVO · ORGOVYX · PADCEV · PROMACTA · Perjeta · Phesgo · QINLOCK · RETACRIT · Reblozyl · SARCLISA · SUTENT · Stivarga · TECENTRIQ · TIBSOVO · VERZENIO · VYXEOS · XTANDI · Xofigo · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (57%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
Hematology & oncology specialists within 10 mi
394
Per 100K population
4.0
County median income
$87,760
Nearest hospital
GLENDALE MEM HOSPITAL & HLTH CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ucar is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with speaking/promotional industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ucar experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Ucar performed 169,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ucar receive payments from pharmaceutical companies?
Yes. Dr. Ucar received a total of $7,411 from 35 companies across 156 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ucar's costs compare to other hematology & oncology specialists in Glendale?
Dr. Ucar's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ucar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Glendale
Browse hematology & oncology specialists in Glendale ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology